Loyal Leverages Vet Chains
Loyal
The key advantage is not just demand for older dog care, it is shelf space inside veterinary systems that already see millions of pets a year. Loyal is building drugs that fit routine checkups and refill workflows, so large clinic groups can add longevity treatment the same way they add chronic meds, diagnostics, and wellness plans. That turns distribution from a cold start problem into a formulary and care pathway decision inside existing vet networks.
-
Mars already has senior pet care packaging inside Banfield, with Senior Care Optimum Wellness Plans launched in June 2025. Banfield says it has more than 1,000 hospitals, over 3 million pets seen each year, and more than 2 million wellness plan clients. That is the kind of installed base that can make a new therapy visible fast once vets decide where it fits in care protocols.
-
Chewy is building a smaller but highly connected channel. Chewy Vet Care launched in 2024, and Chewy now shows clinics across Atlanta, Austin, Denver, and South Florida, tied to pharmacy, virtual vet access, and insurance and wellness products. For Loyal, that matters because the prescription, refill, and home delivery loop can live inside one consumer app.
-
This channel strategy matches how Loyal sells. LOY-002 is a daily pill for senior dogs, while LOY-001 is a periodic injection, and Loyal expects dog owners to pay under $100 per month through recurring veterinary prescriptions. The company has also run a 1,300 dog trial across 70 clinics, which helps it enter vet groups with data generated in real clinic settings, not just lab studies.
The next step is for longevity drugs to be bundled into senior pet care packages, not sold as standalone experiments. As clinic chains build more age specific wellness programs and insurers widen preventive coverage, the winners will be the companies whose products drop cleanly into twice yearly exams, diagnostics, pharmacy refills, and monthly payment plans across large veterinary networks.